Dead money until March, then lift-off to new highsAnybody hoping for Ph2 data anytime soon should not hold their breath. This is not like Ph1 where we were treated to quarterly updates. In Ph2, the updates will not be as frequent.
IMHO, TLT would be wise to hold off until next March when they will have 12-month data on the first cohort of 12 patients. If 8 or more of those patients is NMIBC-free, TLT will have the clinical evidence to support its application to the FDA for Breakthrough designation.
At that point, one could easily see the long-awaited, blue-sky break-out for patient TLT holders.